CTI BioPharma (CTIC) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CTI BioPharma Reports First Quarter 2022 Financial Results
May 12, 2022 4:05 PM EDTStrong U.S. commercial launch of VONJOÂ (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia
VONJO (pacritinib) net product revenue of $2.3 million in less than one month following launch, exceeding initial Company expectations
VONJO included as recommended first- and second-line treatment in NCCN® Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms
... More